Nurix’s therapies control E3 ubiquitin ligases, the key enzymes responsible for protein breakdown within the natural cellular process. With our unique DELigase platform, we can both increase and decrease protein levels, by either harnessing or inhibiting the activity of the appropriate E3 ligase, to treat many different diseases. Currently, we are focused on developing targeted therapies for cancer including novel, small molecule immuno-oncology agents.
Nurix was founded by a team of internationally renowned scientific experts in the E3 ubiquitin ligase regulation and structure field. Since incorporation, the company has built a seasoned team of leaders with wide-ranging backgrounds in small molecule drug development. Nurix is funded by leading life sciences investors and corporate partners and is headquartered in San Francisco, California.